Preparation method and application of novel indole thiazolidone tubulin inhibitor
By developing a novel structure indothiazolidinone compound, as a tubulin inhibitor, the problems of low efficiency and great toxicity of existing colchicine site inhibitors have been solved, and effective inhibition of tumor cells has been achieved and Reducing drug resistance provides new anti-tumor treatment options.
Patent Information
- Application Number
- CN202410936115.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-05
AI Technical Summary
The existing colchicine-site tubulin inhibitors have problems of low efficiency and great toxicity in the treatment of tumors, and there are no effective drugs approved by the FDA to market, which leads to the development of new, highly efficient and low-toxic inhibitors. significance.
A novel structural indothiazolidinone compound was developed, prepared by a specific synthetic route, as a tubulin inhibitor, inhibiting the polymerization of tubulin, thereby effectively inhibiting the growth and invasion of tumor cells.
This compound significantly inhibits the proliferation and invasion of a variety of tumor cells, has good anti-tumor activity, enhances the effectiveness of the drug, reduces drug resistance and toxic side effects, and provides a new potential way to treat tumor diseases.
Smart Images

Figure CN118894849A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a novel indole thiazolidinone small molecule microtubule inhibitor compound, a preparation method thereof, and use thereof as a drug for treating diseases such as tumors. Background Art
[0002] Microtubules play an important role in the process of cell mitosis and have become one of the important targets for the research and development of targeted anticancer drugs. Compared with normal cells, tumor cells have the ability to proliferate abnormally and can rapidly proliferate and deteriorate. Their mitosis process is frequent and their cell cycle is significantly shorter than that of normal cells. Blocking the mitosis process of malignant tumor cells is one of the effective ways to treat cancer. Clinical cancer treatment has shown that microtubule-targeted drugs (MTAs) can effectively treat cancer. Drugs targeting microtubules mainly promote or inhibit the polymerization of microtubules and destroy the dynamic balance of microtubule polymerization to interfere with the formation of tumor cell spindles, block cell division, and then inhibit tumor cell proliferation and cause cell apoptosis.
[0003] Compounds that bind to the colchicine site, vinblastine site, maytansine site, and bilonidin site can promote microtubule depolymerization. Among them, inhibitors that bind to the colchicine site are also called colchicine site inhibitors. The small size and simple pharmacodynamic characteristics of the colchicine site also make most CBSIs have a small molecular weight, and the simple structure is easy to chemically modify to improve pharmacokinetic (PK) properties, efficacy, and reduce toxicity. Studies have shown that many CBSIs can overcome Pgp / β-III tubulin-mediated drug resistance and have anti-angiogenic or anti-vascular effects. Although a large number of colchicine site inhibitors have been reported, none has been approved by the FDA for successful marketing. Therefore, the development of new, efficient, and low-toxic colchicine site tubulin inhibitors is of great significance for the effective treatment of tumors. Summary of the invention
[0004] The present invention aims to provide a novel colchicine-site microtubule inhibitor, which inhibits the polymerization of microtubules and has a good inhibitory effect on the growth, proliferation and invasion of various tumor cells, and reveals its application prospects with anti-tumor activity. Based on the above research results, the present invention is completed.
[0005] To achieve the above object, the technical solution of the present invention is as follows:
[0006] The first aspect of the present invention provides a compound or a pharmaceutically acceptable salt thereof, which has the structure described in the following general formula I:
[0007]
[0008] in,
[0009] n is selected from 1, 2, 3, 4, 5;
[0010] R1 is selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic heterocycle, wherein the substituted alkyl, alkoxy, heterocycloalkyl, aryl, heteroaryl is substituted by 1, 2, 3, 4 or 5 substituents independently selected from the following: -F, -Cl, -Br, -I, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 aldehyde, C1-C6 keto, phenyl, 3-6 membered cycloalkyl;
[0011] R2 is selected from -F, -Cl, -Br, -I, -H, C1-C6 alkyl, C1-C6 alkoxy;
[0012] R3 is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl is substituted by 1, 2, 3, 4 or 5 substituents independently selected from the following: -F, -Cl, -Br, -I, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 aldehyde, C1-C6 keto.
[0013] In some embodiments, R1 is selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, wherein the substituted alkyl, alkoxy is substituted by 1 or 2 substituents independently selected from the following: -F, -Cl, -Br, -I, phenyl, 3-6 membered cycloalkyl.
[0014] In some embodiments, R3 is selected from
[0015]
[0016] In some embodiments, n=1.
[0017] In some embodiments, R1 is selected from -CH3, -CH2CH3,
[0018] R2 is -CH3;
[0019] R3 is selected from
[0020]
[0021] In some embodiments, the compound is selected from:
[0022]
[0023] Another aspect of the present invention provides a method for preparing an indole thiazolidinone compound, wherein the indole thiazolidinone compound is any of the compounds described above.
[0024] Its synthetic route is carried out according to the following route:
[0025]
[0026] First, a compound of general formula II is used as a starting material, and a halogenated derivative undergoes a nucleophilic substitution reaction to obtain a compound of general formula III; the compound of general formula III undergoes a coupling reaction with 2,4-thiazolidinedione to obtain a compound of general formula IV; the compound of general formula IV undergoes a nucleophilic substitution reaction with a halogenated derivative under the action of a base to obtain a compound of general formula V; the tert-butyl ester of the compound of general formula V is hydrolyzed under the action of trifluoroacetic acid to obtain a compound of general formula VI; the compound of general formula VI undergoes an amide condensation reaction with an amine derivative to obtain a compound of general formula I.
[0027] Wherein, R1, R2, R3, and n are as described above.
[0028] The specific synthesis steps of the indole thiazolidinone compound are as follows:
[0029] (1) Synthesis of compounds of formula III:
[0030] The compound of formula II is dissolved in dry tetrahydrofuran, cooled to 0°C in an ice-water bath, and then NaH is slowly added to the above reaction solution. After stirring for 30 minutes, R1X is added to the reaction solution at 0°C, and stirring is continued for 10 minutes. The reaction solution is transferred to room temperature and continued to be stirred, and the reaction is monitored by TLC. Then water is added to the reaction solution to quench the reaction, extracted with ethyl acetate, and the organic phases are combined, washed with water and saturated NaCl aqueous solution in turn, and dried over anhydrous Na2SO4 overnight. The filtrate is filtered to remove the organic solvent under reduced pressure, and the crude product is separated and purified by silica gel column chromatography to obtain the compound of formula III; based on the amount of substance, the amount of compound of formula II: NaH: R1X is 1:1-2:1-2.
[0031] (2) Synthesis of compounds of formula IV:
[0032] The compound of formula III and 2,4-thiazolidinedione are dissolved in acetic acid, and then piperidine is added. The reaction solution is heated to 110°C for reaction, and the reaction is monitored by thin layer chromatography. After the reaction solution is cooled to room temperature, the solvent is removed by rotary evaporation under reduced pressure, and the residue is dissolved in dichloromethane, which is washed with water and saturated NaCl aqueous solution in turn, and dried over anhydrous Na2SO4. The filtrate is filtered to obtain the filtrate, and the organic solvent is removed under reduced pressure. The crude product is separated and purified by silica gel column chromatography to obtain the compound of formula IV; in terms of the amount of substance, the amount of compound of formula III: 2,4-thiazolidinedione: piperidine is 1:1-2:5-10.
[0033] (3) Synthesis of compounds of formula V:
[0034] The compound of formula IV is dissolved in DMF, and then the halogenated derivative and potassium carbonate are added to the reaction solution, reacted at room temperature, and the reaction is monitored by thin layer chromatography. Ethyl acetate is then added to the reaction solution to dilute the reaction solution, washed with water and saturated NaCl aqueous solution in sequence, dried over anhydrous sodium sulfate, filtered to remove anhydrous sodium sulfate, and separated and purified by silica gel column chromatography to obtain a compound of formula V; in terms of the amount of substance, the amount of the compound of formula IV: the halogenated derivative: potassium carbonate is 1:1-2:1-2.
[0035] (4) Synthesis of the compound of formula VI:
[0036] The compound of formula V was dissolved in a mixed solvent of trifluoroacetic acid and dichloromethane (1:1), stirred at room temperature for 3 hours, and the reaction of the raw material was completed by TLC monitoring. Most of the solvent in the reaction solution was removed by rotation, and toluene was added to form an azeotrope with trifluoroacetic acid and then removed by rotation, and the reaction was repeated several times until the residual trifluoroacetic acid was removed. The crude carboxylic acid product was directly used in the next step without further purification.
[0037] (5) Synthesis of compounds of general formula I:
[0038] The crude carboxylic acid product of the compound of the general formula VI is dissolved in dry dichloromethane, and then amine, HATU and DIPEA are added to the reaction solution in sequence, stirred at room temperature, and the reaction is monitored by a thin layer chromatography plate. The reaction solution is then diluted with dichloromethane, washed with water and saturated sodium chloride aqueous solution in sequence, and the organic phase is dried overnight with anhydrous Na2SO4. The filtrate is filtered to remove the organic solvent under reduced pressure, and the crude product is separated and purified by silica gel column chromatography to obtain the compound of the general formula I; in terms of the amount of substance, the amount of the compound of the general formula VI: amine: HATU: DIPEA is: 1:1-2:1-2:3-5.
[0039] The compounds also include pharmaceutically acceptable salts, stereoisomers, esters, prodrugs, solvates and deuterated compounds thereof.
[0040] The third aspect of the present invention provides the use of the above-mentioned compound in the preparation of drugs for tumor-related diseases.
[0041] Furthermore, the disease may also be a disease associated with tubulin.
[0042] The fourth aspect of the present invention provides a pharmaceutical composition comprising the above compound and at least one pharmaceutically acceptable excipient.
[0043] According to common methods, the pharmaceutical composition can be prepared into oral preparations, external preparations, suppositories and sterile injection solutions in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, sprays and the like.
[0044] The non-drug active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and those skilled in the art can determine whether they meet clinical standards.
[0045] Obviously, the above-mentioned pharmaceutical composition or pharmaceutical preparation can be used to treat tumor-related diseases, especially diseases related to microtubules.
[0046] Another aspect of the present invention provides a method for treating tumors, comprising administering a therapeutically effective amount of the above-mentioned compound, pharmaceutical composition or pharmaceutical preparation to a subject.
[0047] The present invention also provides the use of the above-mentioned compound or its pharmaceutically acceptable salt in the preparation of a drug for a tubulin inhibitor. In some embodiments, the drug for the tubulin inhibitor is an anti-tumor drug for the tubulin inhibitor. In some embodiments, the compound is a compound shown in Formula I. In some embodiments, the compound is Compound 1.
[0048] The present invention also provides the use of the above compound or its pharmaceutically acceptable salt in preparing anti-tumor drugs.
[0049] In some embodiments, the tumor is selected from sarcoma, lung cancer, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colorectal adenoma, thyroid cancer, liver cancer, adrenal cancer, glioma, endometrial cancer, melanoma, kidney cancer, bladder cancer, uterine corpus cancer, cervical cancer, vaginal cancer, ovarian cancer, multiple myeloma, esophageal cancer, leukemia, brain cancer, oral and pharyngeal cancer, laryngeal cancer, neoplasia, lymphoma, breast cancer, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia and Waldenstrom's disease. In some embodiments, the tumor is selected from breast cancer, ovarian cancer, cervical cancer, uterine cancer, prostate cancer, kidney cancer, urethral cancer, bladder cancer, liver cancer, stomach cancer, endometrial cancer, salivary gland cancer, pancreatic cancer, lung cancer and lymphoma.
[0050] Beneficial technical effects of one or more of the above technical solutions:
[0051] (1) The indole thiazolidinone microtubule inhibitor reported for the first time in the present invention has a novel structure and is of great significance for enhancing the effectiveness of drugs, preventing drug resistance and reducing toxic side effects.
[0052] (2) The compounds of the present invention are novel indole thiazolidinone microtubule inhibitors with a mechanism of action similar to that of colchicine, which inhibits the polymerization of microtubules and disrupts the balance of microtubule assembly, and can thus be used to treat tumors and other related diseases, and therefore have good prospects for practical application.
[0053] Definitions of terms used in the present invention: Unless otherwise stated, the initial definitions provided for groups or terms in this document apply to the groups or terms throughout the specification; for terms that are not specifically defined in this document, the meaning that a person skilled in the art can give them should be given based on the disclosure and context.
[0054] The minimum and maximum carbon atom content in a hydrocarbon group is indicated by a prefix, for example, the prefix C a~b Alkyl refers to any alkyl group containing from "a" to "b" carbon atoms. 1~6 Alkyl refers to a straight or branched alkyl group containing 1 to 6 carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl and various branched isomers thereof.
[0055] "Alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include: methoxy, ethoxy, propoxy, butoxy. Alkoxy can be optionally substituted or unsubstituted.
[0056] "Cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, etc.; polycyclic cycloalkyls include spirocyclic, annular and bridged cycloalkyls. Cycloalkyls may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from halogen, hydroxyl, oxo, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, 3- to 6-membered cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl is optionally substituted by halogen, hydroxy, nitro, cyano or amino.
[0057] "Heterocycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent containing 3 to 20 ring atoms, one or more of which is selected from nitrogen, oxygen or S(O) m (wherein m is an integer from 0 to 2) heteroatoms, but excluding the ring portion of -OO-, -OS- or -SS-, the remaining ring atoms are carbon. Preferably, it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably, it contains 3 to 7 ring atoms. Non-limiting examples of "heterocycloalkyl" include:
[0058]
[0059] etc.
[0060] The heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
[0061] wait.
[0062] The heterocycloalkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from halogen, hydroxy, oxo, cyano, amino, C 1-6 Alkyl, C 1-6 Alkoxy, 3- to 6-membered cycloalkyl or 3- to 6-membered heterocycloalkyl, wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl is optionally substituted by halogen, hydroxy, nitro, cyano or amino.
[0063] "Aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group with a conjugated π electron system, preferably 6- to 12-membered, such as phenyl and naphthyl. The aryl ring may be fused to a heteroaryl, heterocycloalkyl or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring, non-limiting examples of which include:
[0064]
[0065] Aryl may be substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from halogen, hydroxy, oxo, nitro, cyano, C 1-6 Alkyl, C 1-6 Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, 3- to 6-membered cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 Cycloalkenyloxy, 5 to 6 membered aryl or heteroaryl, the C 1-6 Alkyl, C 1-6Alkoxy, C 2-6 Alkenyloxy, C 2-6 Alkynyloxy, 3 to 6-membered cycloalkoxy, 3 to 6-membered heterocycloalkoxy, 3 to 8-membered cycloalkenyloxy, 5 to 6-membered aryl or heteroaryl are optionally substituted with one or more selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl or C 1-6 Alkoxy substitution.
[0066] "Heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 6 to 12 members, more preferably 5 or 6 members. For example. Non-limiting examples include: imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl, triazolyl, indazolyl, benzimidazolyl, wait.
[0067] The heteroaryl ring may be fused to an aryl, heterocycloalkyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring, non-limiting examples of which include:
[0068]
[0069] The heteroaryl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl or C 1-6 Alkoxy.
[0070] "Halogen" is fluorine, chlorine, bromine or iodine.
[0071] As used herein, the term "independently" or "each independently" means that in a compound, for a given variable in multiple instances, the same or different values may be selected.
[0072] Obviously, according to the above contents of the present invention, in accordance with the common technical knowledge and effective means in the field, without departing from the above basic technical ideas of the present invention, other various forms of modifications, replacements or changes can be made. BRIEF DESCRIPTION OF THE DRAWINGS
[0073] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0074] Figure 1 The antiproliferative activity of compound 1 on A549, MCF-7 and HepG2 cells.
[0075] Figure 2 The effect of compound 1 on microtubule polymerization in vitro.
[0076] Figure 3 The effect of compound 1 on the microtubule network of A549MCF-7 and HepG2 cells. DETAILED DESCRIPTION
[0077] The following embodiments are used to better illustrate the present invention, but the present invention is not limited to the following embodiments.
[0078] Example 1: Preparation of Compound 1
[0079]
[0080] Synthesis of compound 17:
[0081]
[0082] 2-Methylindole-3-carboxaldehyde (200 mg, 1.26 mmol) was dissolved in 5 mL of dry tetrahydrofuran, cooled to 0°C in an ice-water bath, and then NaH (33.17 mg, 1.38 mmol) was slowly added to the above reaction solution. After stirring for 30 minutes, iodomethane (267.49 mg, 1.88 mmol) was added to the reaction solution at 0°C. After stirring for 10 minutes, the reaction solution was transferred to room temperature and continued to stir for 6 hours. TLC monitored the reaction to be complete. 30 mL of water was added to the reaction solution to quench the reaction, extracted with ethyl acetate, and the organic phases were combined and washed with water and saturated NaCl aqueous solution in turn, and dried over anhydrous Na2SO4 overnight. The filtrate was filtered, and the organic solvent was removed under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain 150 mg of compound 17 with a yield of 68.9%.
[0083] Synthesis of compound 18:
[0084]
[0085] Compound 17 (100 mg, 577.32 μmol) and 2,4-thiazolidinedione (67.62 mg, 577.32 μmol) were dissolved in 2.5 mL of acetic acid, and then piperidine (285.14 μL, 2.89 mmol) was added. The reaction solution was heated to 110°C and reacted for 16 hours. After the reaction solution was cooled to room temperature, the solvent was removed by rotary evaporation under reduced pressure, and the residue was dissolved in 50 mL of dichloromethane, washed with water and saturated NaCl aqueous solution in turn, and dried over anhydrous Na2SO4. The filtrate was filtered, and the organic solvent was removed under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain 65 mg of compound 18 with a yield of 41.34%.
[0086] Synthesis of compound 19:
[0087]
[0088] Compound 18 (200.00 mg, 734.42 μmol) was dissolved in 5 mL DMF, and then tert-butyl bromoacetate (286.51 mg, 1.47 mmol) and potassium carbonate (203.00 mg, 1.47 mmol) were added to the above reaction solution. After reacting at room temperature for 12 hours, the reaction was monitored by a thin layer chromatography plate. 60 mL of ethyl acetate was added to the above reaction solution to dilute the reaction solution, washed with water 3 times, washed with a saturated sodium chloride solution 3 times, dried over anhydrous sodium sulfate, filtered to remove anhydrous sodium sulfate, and separated and purified by silica gel column chromatography to obtain 220 mg of compound 19 with a yield of 77.51%.
[0089] Synthesis of compound 1:
[0090]
[0091] Compound 19 (100.00 mg, 258.75 μmol) was dissolved in a mixed solvent of 3 mL trifluoroacetic acid and 3 mL dichloromethane, stirred at room temperature for 3 hours, and the reaction of the raw materials was completely monitored by TLC. Most of the solvent in the reaction solution was removed by spinning, and toluene was added to form an azeotrope with trifluoroacetic acid and then removed by spinning, and the residual trifluoroacetic acid was removed repeatedly until the residual trifluoroacetic acid was removed. The crude carboxylic acid product was directly used for the next step of reaction without further purification. The above crude carboxylic acid product was dissolved in 10 mL dry dichloromethane, and then amine (43.21 mg, 310.51 μmol), HATU (147.58 mg, 388.13 μmol) and DIPEA (225.36 μL, 1.29 mmol) were added to the reaction solution in turn, and stirred at room temperature for 6 hours. The reaction solution was diluted with 60 mL dichloromethane, washed with water and saturated sodium chloride aqueous solution in turn, and the organic phase was dried overnight with anhydrous Na2SO4. The filtrate was filtered and the organic solvent was removed under reduced pressure. The crude product was separated and purified by silica gel column chromatography to obtain 68 mg of compound 1 with a yield of 58.21%.
[0092] 1 H NMR(400MHz, CDCl3)δ9.26(s,1H),7.95(s,1H),7.77–7.44(m,2H),7.28–6.99(m,1H),6.57(dd,J=15.0,2.8Hz ,1H),6.10–5.74(m,3H),4.60(s,2H),3.83(s,3H),3.16(d,J=2.0Hz,2H),2.97(d,J=12.4Hz,2H),2.65(s,3H). 13C NMR (100MHz, DMSO-d6) δ170.34,167.68,166.05,144.54,140.30,136.93,128.91,125.35,124. 43,122.06,120.51,120.25,110.84,106.49,97.81,97.56,45.25,32.83,30.54,22.50,12.51.
[0093] Example 2: Molecular docking
[0094] This study used the tubulin-colchicine complex crystal structure from the PDB database (PDB: 1SA0). The original crystal structure was preprocessed using Discovery Studio 3.5, and then Autodock Vina molecular docking was used to dock colchicine and compound 1 into the active site.
[0095] The results showed that colchicine and compound 1 could form good interactions with the key residues of tubulin, with Vinascore scores of -10.9 and -9.7 kJ·mol, respectively. -1 Compound 1 formed hydrogen-bonding interactions with residues αGLN11, βASN249, ASN101, and βASP251. Compound 1 formed π-π interactions with residues βLYS254, βMET259, and βCYS241. The compound formed hydrophobic interactions with residues αALA180, βLYS352, βALA316, βALA250, βLEU248, and βILE318. Residue βLEU255 formed a conjugated interaction with compound 1.
[0096] Example 3: CKK8 test for anti-proliferative activity
[0097] A549, MCF-7 and hepG2 cells were cultured at 5×10 3 Inoculate in 96-well plates. Treat cells with different concentrations of compound 1 (0uM, 10uM, 20uM, 40uM, 60uM, 80uM). At 48h, 10μL of CCK-8 solution was added to each well and incubated in an incubator. After 1h, the absorbance at 450nm was measured using Bio-Tek enzyme markers.
[0098] The results of CCK8 assay showed that compound 1 inhibited the activity of A549, HepG2 and MCF-7 cells in a concentration-dependent manner, and its IC 50 40.47, 36.39 and 32.25 μM respectively ( Figure 1 ).
[0099] Example 4: In vitro microtubule polymerization experiment
[0100] 100uL of PIPES buffer (80mM PIPES, 0.5mM EGTA, 2mM MgCl2) with a pH of 6.9 and containing 1mM GTP was added to 1mg tubulin to make the concentration of tubulin solution 10mg / mL. After mixing, it was divided into 10 tubes, 10uL in each tube. In a 384-well microplate preheated at 37°C, the total reaction system was 50uL. First, 10μL (10mg / mL) tubulin solution and 28μL microtubule polymerization buffer (containing 1mM GTP, 26.8% glycerol, so that the proportion of glycerol in the total system is 15%) and 10μL of drug (so that the total system concentration of 50uL is 0μM, 40μM and 60μM) of compound 1 positive control colchicine and paclitaxel concentration are 1μM, mix well, place in a full-wavelength microplate reader for detection, detect at 340nm, record every 30s, a total of 60min. Finally, the tubulin polymerization rate of the blank control is 100%, and the inhibition rate of the compound destroying tubulin polymerization is calculated.
[0101] The results are as follows Figure 2 As shown, the curve of the paclitaxel-treated group is above the blank control group, indicating that paclitaxel has a promoting effect on the polymerization of microtubules. The curves of the compound 1 and colchicine-treated groups are both below the blank control group, indicating that the in vitro microtubule polymerization experimental results of compound 1 and colchicine are consistent, both have an inhibitory effect on microtubule polymerization, and have a concentration-dependent inhibitory effect. The experimental results show that the inhibitory effect of compound 1 on microtubule polymerization is the same as that of colchicine on microtubules.
[0102] Example 5 Indirect immunofluorescence experiment
[0103] A549, MCF-7 and HepG2 cells were cultured at 5×10 4 Cells were inoculated into a 6-well plate slide at 100 μg / mL. After culturing for 24 h, different concentrations (20, 40 μM) of compound 1 were added. After culturing for 24 h, the cells were washed three times with PBS. Subsequently, the cells were fixed with 4% paraformaldehyde for 15 min, permeated with 0.2% Triton-X100 for 10 min, and blocked with 5% BSA for 30 min. The cells were then incubated with the primary antibody at 4 °C overnight, the secondary antibody was added for incubation at room temperature for 1 h, and DAPI was used for staining for 5 min. Images were acquired using a two-photon laser confocal microscope.
[0104] The results are as follows Figure 3As shown in the figure, the effects of different concentrations of compound 1 on the microtubule network of A549, MCF-7 and HepG2 cells. The microtubule network of cells in the blank control group diffused from the inside to the outside in an orderly manner, and was distributed in bundles to support the spindle shape of the cells. However, the cells treated with compound 1 shrank, changing from the spindle shape of normal cells to round or polygonal, and the microtubule morphology became disordered, with a trend and concentration-dependent increase. Taking cells treated with 40μM compound 1 as an example, the morphology of the microtubules changed, indicating that compound 1 destroyed the morphology of the microtubules.
[0105] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.
Claims
1. A compound or a pharmaceutically acceptable salt thereof, It is characterized in that It has the structure shown in general formula I: in, n is selected from 1, 2, 3, 4, 5; R 1 is selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted aromatic heterocycle, wherein the substituted alkyl, alkoxy, heterocycloalkyl, aryl, heteroaryl is substituted by 1, 2, 3, 4 or 5 substituents independently selected from the following: -F, -Cl, -Br, -I, nitro, hydroxyl, amino, cyano, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, C 1 -C 6 Aldehyde, C 1 -C 6 Keto, phenyl, 3-6 membered cycloalkyl; R 2 Selected from -F, -Cl, -Br, -I, -H, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy; R 3 is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, wherein the substituted cycloalkyl, heterocycloalkyl, aryl, heteroaryl is substituted by 1, 2, 3, 4 or 5 substituents independently selected from the following: -F, -Cl, -Br, -I, nitro, hydroxy, amino, cyano, C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, C 1 -C 6 Alkylthio, C 1 -C 6 Aldehyde, C 1 -C 6 Keto.
2. The compound according to claim 1, It is characterized in that R 1 is selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 1 -C 6 Alkoxy, wherein the substituted alkyl, alkoxy is substituted by 1 or 2 substituents independently selected from the following: -F, -Cl, -Br, -I, phenyl, 3-6 membered cycloalkyl.
3. The compound according to claim 1, It is characterized in that R 3 Selected from 4. The compound according to claim 1, It is characterized in that n=1; R 1 Selected from -CH 3 , -CH 2 CH 3 , R 2 -CH 3 ; R 3 Selected from 5. The compound according to claim 1, It is characterized in that The compound is selected from:
6. The compound according to any one of claims 1 to 5, It is characterized in that The compound is a microtubule protein inhibitor.
7. A method for preparing the compound according to claim 1, It is characterized in that The preparation method comprises the following steps: First, a compound of general formula II is used as a starting material, and a halogenated derivative undergoes a nucleophilic substitution reaction to obtain a compound of general formula III; the compound of general formula III undergoes a coupling reaction with 2,4-thiazolidinedione to obtain a compound of general formula IV; the compound of general formula IV undergoes a nucleophilic substitution reaction with a halogenated derivative under the action of a base to obtain a compound of general formula V; the tert-butyl ester of the compound of general formula V is hydrolyzed under the action of trifluoroacetic acid to obtain a compound of general formula VI; the compound of general formula VI undergoes an amide condensation reaction with an amine derivative to obtain a compound of general formula I, wherein R 1 , R 2 , R 3 , n as described in claim 1.
8. An ester, prodrug, solvate or deuterated compound of the compound of any one of claims 1 to 6.
9. A pharmaceutical composition comprising the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or an ester, prodrug, solvate or deuterated compound of the compound according to claim 8, and a pharmaceutically acceptable excipient.
10. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, or an ester, prodrug, solvate or deuterated compound of the compound according to claim 8 in the preparation of an anti-tumor drug.
